Enjoy complimentary customisation on priority with our Enterprise License!
The pulmonary arterial hypertension (PAH) drugs market size is estimated to grow at a CAGR of 6.62% between 2022 and 2027. The pulmonary arterial hypertension drugs market size is forecast to increase by USD 2.08 billion. The growth of the market depends on several factors, including the growing prevalence of PAH, the growing geriatric population, and the increasing risk factors for cardiovascular diseases.
This pulmonary arterial hypertension (PAH) drugs market report extensively covers market segmentation by route of administration (oral, injectable, and inhalation), action mechanism (prostacyclin analogs, endothelin receptor antagonists (ERAS), phosphodiesterase (PDE) inhibitors, and soluble guanylate cyclase stimulators (SGCSS)), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, View Report Sample
The growing prevalence of PAH is notably driving the market growth, although factors such as a shortage of healthcare professionals may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Growing prevalence of PAH is the key factor driving the growth of the global pulmonary arterial hypertension drugs market. With the prevalence of PAH disease, the market for PAH drugs is expanding. During the forecast period, rising prevalence of PAH disease and associated hospitalizations for treatment are expected to increase the demand for the corresponding drugs. When PAH occurs, the small arteries in the lungs thicken and narrow. Blood flow through the lungs is blocked by PAHs. As a result, blood pressure in the lungs increases, making it difficult for the heart to pump blood through narrowed arteries. A person's heart gradually loses its capacity to pump blood effectively throughout the body.
Women between the ages of 30 and 60 are most affected by PAH. According to the National Organization for Rare Disorders (NORD), women are three to five times more likely to develop PAH than men. Moreover, according to a study by the National Organization for Rare Disorders, around 500-1,000 new cases of PAH are recorded in the US every year or 1-2 cases per billion people. Thus, the growing incidence of PAH is expected to drive the growth of the global PAH drugs market during the forecast period.
Increasing awareness regarding PAH is the primary trend in the global pulmonary arterial hypertension drugs market. With the prevalence of PAH disease, the market for PAH drugs is expanding. During the forecast period, rising prevalence of PAH disease and associated hospitalizations for treatment are expected to increase the demand for the corresponding drugs. When PAH occurs, the small arteries in the lungs thicken and narrow. Blood flow through the lungs is blocked by PAHs. As a result, blood pressure in the lungs increases, making it difficult for the heart to pump blood through narrowed arteries. There are numerous treatments on the market that aid in reducing the progression of diseases and enhancing the quality of life.
Additionally, the approval of a small number of potent medications and the existence of a promising pipeline are some key elements that will propel the growth of the global PAH drugs market during the forecast period. Additionally, favorable government policies will help in increasing the demand for PAH treatments, which in turn will drive the growth of the global PAH drugs market during the forecast period.
Shortage of healthcare professionals is major challenge to the growth of the global pulmonary arterial hypertension drugs market. Our network of medical facilities, laboratories, and diagnostic centers spans the globe. The growing world population has increased the burden of running an effective healthcare system. The growth of the healthcare industry is hampered by several factors, such as high infrastructure, machinery and equipment costs, and lack of qualified staff. According to the WHO, there will be 12.9 billion fewer healthcare workers in the world by 2035 than in 2021.
Moreover, several factors, such as an aging workforce, a decline in the number of people entering the field, early retirements, inadequate training, and increased demands from an aging and growing population, all these factors will lead to a shortage of healthcare professionals. Thus, a shortage of healthcare professionals can become a major challenge to the growth of the global PAH drugs market during the forecast period.
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Pulmonary Arterial Hypertension Drugs Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Aerami Therapeutics Holdings Inc.: The company offers pulmonary arterial hypertension drug solutions such as Orphan. Also, this segment focuses on developing inhaled therapies to treat severe respiratory and chronic diseases.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth by the oral segment will be significant during the forecast period. Oral administration comprises tablets and suspensions, and tablets can be branched as film-coated tablets and extended-release tablets. Since the study of widespread animal and human efficacy and safety is not required in these formulations, the market segment is likely to witness growth during the forecast period.
Get a glance at the market contribution of various segments View the PDF Sample
The oral segment was valued at USD 2.93 billion in 2017 and continued to grow until 2021. There are different oral drugs available for the treatment of PAH. The endothelin receptor antagonists (ERAs), bosentan and sitaxentan, and sildenafil are all used as oral medications to treat symptomatic, moderate-to-severe PAH. For instance, Ambrisentan is a brand-new oral ERA that selectively targets the ET(A) receptor and has a higher ET receptor affinity than bosentan. Ambrisentan (5 or 10 mg/day) has been shown to be secure and efficient in placebo-controlled, randomized clinical trials (RCTs). Similarly, Bosentan, an oral dual ETA and ETB receptor antagonist increase exercise tolerance and cardiopulmonary hemodynamics in PAH patients. Thus, the growing use of oral drugs to treat PAH is expected to drive the growth of the oral administration segment in the global PAH drugs market during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 45% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. North America dominates the global PAH drugs market and will hold the largest revenue share in 2022. A substantial portion of the market in focus is attributable to the developed healthcare systems in the US and Canada that make access to cutting-edge therapeutics easier. In addition, increasing awareness, high diagnostic rates, and favourable government initiatives are driving market growth in the region. Regional market expansion is also supported by a well-designed reward structure and the presence of key players. The need for advanced medical facilities to treat pulmonary arterial hypertension is driven by the rising prevalence and high diagnosis rates of infectious and chronic diseases in this region.
The outbreak of COVID-19 in 2020 significantly led to a decline in demand for PAH treatments in North America. However, the lockdowns were lifted in the second half of 2020 owing to large-scale vaccination drives across North America. This led to the resumption of operations in clinics and hospitals that offer PAH treatments, which increased the demand for PAH drugs in the first half of 2021. Such factors are expected to open up new opportunities for PAH treatments and will drive the growth of the PAH drugs market in North America during the forecast period.
The pulmonary arterial hypertension drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Pulmonary Arterial Hypertension (PAH) Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
172 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.62% |
Market growth 2023-2027 |
USD 2.08 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
5.94 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 45% |
Key countries |
US, Canada, UK, Germany, and Japan |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Aerami Therapeutics Holdings Inc., Aerovate Therapeutics Inc., Alembic Pharmaceuticals Ltd., Asklepion Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eiger BioPharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Reata Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corp., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.